← All Sab Biotherapeutics, INC filings

Sab Biotherapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SABS
Sab Biotherapeutics, INC
10-K: SAB Biotherapeutics Reports Positive Phase 1 Results for Type 1 Diabetes Therapy SAB-142; Plans Phase 2b Trial
SAB Biotherapeutics announces positive Phase 1 clinical results for SAB-142, a potential disease-modifying therapy for Type 1 Diabetes, and plans to advance to a Phase 2b trial in 2025.
NASDAQ
SABS
Sab Biotherapeutics, INC
10-K: SAB Biotherapeutics Outlines Share Structure and Pipeline in 10-K Filing
SAB Biotherapeutics details its registered securities, including common stock and warrants, and provides an overview of its clinical-stage pipeline in its latest 10-K filing.